MX9302011A - Derivados de indol. - Google Patents

Derivados de indol.

Info

Publication number
MX9302011A
MX9302011A MX9302011A MX9302011A MX9302011A MX 9302011 A MX9302011 A MX 9302011A MX 9302011 A MX9302011 A MX 9302011A MX 9302011 A MX9302011 A MX 9302011A MX 9302011 A MX9302011 A MX 9302011A
Authority
MX
Mexico
Prior art keywords
indol
derivatives
disorders
compounds
useful
Prior art date
Application number
MX9302011A
Other languages
English (en)
Inventor
John E Macor
Martin James Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9302011A publication Critical patent/MX9302011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Estos compuestos son útiles para tratar migraña y otros transtornos que son nuevos.
MX9302011A 1992-04-07 1993-04-06 Derivados de indol. MX9302011A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86473792A 1992-04-07 1992-04-07

Publications (1)

Publication Number Publication Date
MX9302011A true MX9302011A (es) 1994-03-31

Family

ID=25343950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302011A MX9302011A (es) 1992-04-07 1993-04-06 Derivados de indol.

Country Status (26)

Country Link
US (7) US5747501A (es)
EP (1) EP0635017A1 (es)
JP (1) JP2644088B2 (es)
KR (1) KR0179072B1 (es)
CN (2) CN1050841C (es)
AU (1) AU670579B2 (es)
BR (1) BR9306201A (es)
CA (1) CA2133413C (es)
CZ (1) CZ281763B6 (es)
EG (1) EG20226A (es)
FI (1) FI931558L (es)
HR (1) HRP930752A2 (es)
HU (1) HUT64062A (es)
IL (1) IL105206A (es)
MX (1) MX9302011A (es)
MY (1) MY108909A (es)
NO (1) NO303388B1 (es)
NZ (1) NZ251086A (es)
PL (1) PL172405B1 (es)
RU (1) RU2101283C1 (es)
SK (1) SK280193B6 (es)
TW (1) TW341565B (es)
UA (1) UA27467C2 (es)
WO (1) WO1993020073A1 (es)
YU (1) YU48931B (es)
ZA (1) ZA932440B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
CA2169179C (en) * 1993-08-31 2000-02-29 John E. Macor 5-arylindole derivatives
EP0759918A1 (en) * 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
GB9415575D0 (en) * 1994-08-02 1994-09-21 Merck Sharp & Dohme Therapeutic agents
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9423682D0 (en) * 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
WO1996017842A1 (en) * 1994-12-06 1996-06-13 Merck Sharp & Dohme Limited Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
BR9609744A (pt) * 1995-07-31 1999-03-02 Shionogi & Co Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2
GB9519558D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
AU5194999A (en) * 1998-08-07 2000-02-28 Takeda Chemical Industries Ltd. Benzothiepin derivatives, process for the preparation of the same and uses thereof
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
KR100985140B1 (ko) * 2001-12-20 2010-10-05 와이어쓰 엘엘씨 5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민 유도체
RU2218189C1 (ru) * 2002-05-28 2003-12-10 Нижегородская государственная медицинская академия Способ лечения мигрени в межприступном периоде заболевания
US7041697B2 (en) * 2002-09-12 2006-05-09 Wyeth Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan
CA2635010A1 (en) * 2005-12-30 2007-07-19 Amjad Ali Oxazolidinone derivatives as cetp inhibitors
AU2009304293B2 (en) * 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US20100217013A1 (en) * 2008-12-15 2010-08-26 Wenge Li Enantioselective process for the preparation of zolmitriptan
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
BR112018071617A2 (pt) * 2016-04-28 2019-02-19 Jiangsu Hengrui Medicine Co., Ltd. método para preparar inibidor de tirosina quinase e derivado do mesmo
CN115380028A (zh) * 2020-02-04 2022-11-22 明德赛特制药公司 用于治疗cns病症的作为血清素能致幻剂的3-吡咯烷-吲哚衍生物
WO2025104491A1 (en) 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
US4689336A (en) * 1981-01-02 1987-08-25 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine 2,4-diones
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
FR2601008B1 (fr) * 1986-07-03 1990-03-30 Sanofi Sa Procede de synthese stereospecifique de derives de l'indole
WO1988009661A1 (en) * 1987-06-10 1988-12-15 Pfizer Inc. Oxazolidin-2-one derivatives as hypoglycemic agents
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
KR100215627B1 (ko) * 1990-06-07 1999-08-16 레슬리 제인 에드워즈 치료용 헤테로사이클 화합물
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
CA2091562C (en) * 1990-10-15 2001-03-27 John Eugene Macor Indole derivatives useful in psychotherapeutics
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (es) * 1991-02-12 1995-11-21 Pfizer
DE69230803T2 (de) 1991-11-25 2000-12-07 Pfizer Inc., New York 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
EP0545478A1 (en) * 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
US5409941A (en) 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (es) 1992-03-05 1996-10-11 Pfizer
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
UA34452C2 (uk) 1992-04-10 2001-03-15 Пфайзер Інк. Похідні ациламіноіндолу, що проявляють серотонінову 5-нт1 агоністичну активність та похідні аміноіндолу як проміжні сполуки
JP7121942B2 (ja) 2018-04-10 2022-08-19 アサヒビール株式会社 発泡性飲料移充填方法
JP7121943B2 (ja) 2018-04-27 2022-08-19 日本ゼオン株式会社 レジストパターン形成方法

Also Published As

Publication number Publication date
EG20226A (en) 1997-12-31
HUT64062A (en) 1993-11-29
UA27467C2 (uk) 2000-09-15
NO943762L (no) 1994-10-06
CA2133413A1 (en) 1993-10-14
JPH07504919A (ja) 1995-06-01
YU23893A (sh) 1996-10-09
NO303388B1 (no) 1998-07-06
NO943762D0 (no) 1994-10-06
RU94045897A (ru) 1996-09-10
IL105206A (en) 1999-04-11
WO1993020073A1 (en) 1993-10-14
SK280193B6 (sk) 1999-09-10
CA2133413C (en) 2001-04-10
CN1050841C (zh) 2000-03-29
US5747501A (en) 1998-05-05
US6410739B1 (en) 2002-06-25
CZ246494A3 (en) 1995-06-14
AU670579B2 (en) 1996-07-25
FI931558A7 (fi) 1993-10-08
FI931558L (fi) 1993-10-08
RU2101283C1 (ru) 1998-01-10
AU3789893A (en) 1993-11-08
US6465500B1 (en) 2002-10-15
NZ251086A (en) 1996-09-25
TW341565B (en) 1998-10-01
US6436957B1 (en) 2002-08-20
CN1083443C (zh) 2002-04-24
EP0635017A1 (en) 1995-01-25
ZA932440B (en) 1994-10-05
US6150388A (en) 2000-11-21
KR950700906A (ko) 1995-02-20
HU9301003D0 (en) 1993-06-28
CZ281763B6 (cs) 1997-01-15
US6387941B1 (en) 2002-05-14
KR0179072B1 (ko) 1999-03-20
BR9306201A (pt) 1998-06-23
HRP930752A2 (en) 1994-10-31
CN1082543A (zh) 1994-02-23
IL105206A0 (en) 1993-07-08
JP2644088B2 (ja) 1997-08-25
FI931558A0 (fi) 1993-04-06
SK120694A3 (en) 1995-05-10
CN1225362A (zh) 1999-08-11
US6387937B1 (en) 2002-05-14
MY108909A (en) 1996-11-30
PL172405B1 (en) 1997-09-30
YU48931B (sh) 2002-12-10

Similar Documents

Publication Publication Date Title
MY131298A (en) 5-heteroyl indole derivatives
NO964236L (no) Anvendelse av serotonin-antagonister (5HT3) for behandling av fibromyalgi
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
FI954944A7 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina käytettäväksi migreenin hoitoon
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
EA199800667A1 (ru) Новые фенантридины
SE8702109D0 (sv) Tetrahydronaphthalin- und indanderivate
ES2177112T3 (es) Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.
RU94042393A (ru) Галихондрины, родственные соединения и способ лечения опухоли у млекопитающих
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
DE69530860D1 (de) Behandlung der entzündung des sehnervs
FI941413L (fi) Indolijohdannaiset migreenin hoitoon
MX9302931A (es) Nuevas 4-aza-5&-colestan-onas 7b-substituidas como inhibidores de 5&-reductasa.
NO943762L (no) Indolderivater som 5-HT 1 agonister
TR199900505T2 (es)
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
ES2064119T3 (es) Nuevos derivados de aminobenzosultam como inhibidores de la lipoxigenasa.
MX9302951A (es) Composicion farmaceutica para tratar la hiperproliferacion celular.
DK0828851T3 (da) Tripeptidylpeptidaseinhibitorer
BG100248A (bg) Инхибитори на скваленсинтетаза
ES2059779T3 (es) Compuestos anti-androgenos.
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation